Core Viewpoint - Anxu Bio experienced a decline in stock price and revenue, indicating potential challenges in its financial performance and market position [1][2]. Financing and Trading Activity - On August 27, Anxu Bio's stock fell by 2.70%, with a trading volume of 46.83 million yuan. The financing buy-in amounted to 15.09 million yuan, while financing repayment was 14.76 million yuan, resulting in a net financing buy of 0.33 million yuan [1]. - As of August 27, the total financing and securities lending balance for Anxu Bio was 97.20 million yuan, which represents 1.88% of its market capitalization. This financing balance is above the 60th percentile of the past year, indicating a relatively high level [1]. - In terms of securities lending, there were no shares repaid or sold on August 27, with a lending balance of 0.00 shares, placing it in the 90th percentile of the past year, also indicating a high level [1]. Financial Performance - As of June 30, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period. The average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2]. - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%. The net profit attributable to shareholders was 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Shareholder Composition - As of June 30, 2025, among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period. Meanwhile,招商景气优选股票A reduced its holdings by 10,000 shares to 600,000 shares, and博时凤凰领航混合A entered the list as a new shareholder with 528,900 shares [2].

Core Insights - Anxu Biotech's stock increased by 0.86% on August 25, with a trading volume of 38.6154 million yuan [1] - The company reported a financing net purchase of 1.5327 million yuan on the same day, with a total financing balance of 96.5234 million yuan, representing 1.79% of its market capitalization [1] - For the first half of 2025, Anxu Biotech's revenue was 230 million yuan, a year-on-year decrease of 7.42%, and the net profit attributable to shareholders was 59.3059 million yuan, down 48.57% year-on-year [2] Financing and Trading Activity - On August 25, Anxu Biotech had a financing buy amount of 8.0656 million yuan and a financing repayment of 6.5328 million yuan, resulting in a net financing purchase of 1.5327 million yuan [1] - The total financing and securities lending balance was 96.5234 million yuan, which is above the 50th percentile level for the past year, indicating a high level of financing activity [1] - There were no securities lent or sold on August 25, with the securities lending balance also at zero, indicating a lack of short-selling activity [1] Shareholder and Dividend Information - As of June 30, 2025, Anxu Biotech had 6,024 shareholders, an increase of 1.5% from the previous period, while the average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2] - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2] - Notable institutional shareholders include GF Value Core Mixed Fund and others, with some changes in holdings reported [2]

Group 1 - The first meeting of the third board of directors of Hangzhou Anxu Biotechnology Co., Ltd. was held on August 22, 2025, with all seven directors present [1] - The board unanimously elected Mr. Ling Shisheng as the chairman of the third board of directors, with a term consistent with the current board [2] - Ms. Jiang Xueying was elected as the vice chairman of the third board of directors, also with a term consistent with the current board [2] Group 2 - The board approved the establishment of specialized committees, including the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with terms aligned with the current board [2] - Mr. Ling Shisheng was appointed as the general manager of the company, with a term consistent with the current board [2] - Ms. Jiang Xueying, Mr. Dong Wenkun, and Mr. Wei Wentao were appointed as vice general managers, with terms consistent with the current board [2][3] Group 3 - Ms. Jiang Xueying was appointed as the financial director, with a term consistent with the current board [3] - Mr. Han Jun was appointed as the secretary of the board, with a term consistent with the current board [3] - Ms. Yu Jun was appointed as the representative for securities affairs, with a term consistent with the current board [3]

Core Points - The company held a shareholders' meeting on August 22, 2025, in Hangzhou, Zhejiang Province, with a total of 46 ordinary shareholders present, representing 81,577,525 voting rights, which accounts for 64.1924% of the company's total voting rights [1][2][3] - The meeting adopted a combination of on-site and online voting methods, and all voting procedures complied with the Company Law and the company's articles of association [1][2] - All non-cumulative voting proposals were approved, with the majority of votes in favor, including the election of non-independent directors and independent directors [2][3] Voting Results - The proposal to elect Ling Shisheng as a non-independent director received 81,524,714 votes in favor, accounting for 99.9352% of the votes [1][2] - The proposal to elect Jiang Xueying as a non-independent director received 81,526,924 votes in favor, accounting for 99.9379% of the votes [1][2] - The independent director election proposals also received high approval rates, with all candidates receiving over 99.6500% of the votes in favor [2][3] Legal Compliance - The meeting and voting procedures were confirmed to be in accordance with the relevant laws and regulations, ensuring the legality and validity of the resolutions passed [3]

证券代码：688075 证券简称：安旭生物 公告编号：2025-027 杭州安旭生物科技股份有限公司 关于完成董事会换届选举暨聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"） 于 2025 年 8 月 22 日召开 2025 年第一次临时股东大会，选举产生的第三届董事会成员，与公 司于 2025 年 8 月 6 日召开的职工代表大会选举的职工代表董事共同组成第三届董 事会。同日，公司召开第三届董事会第一次会议，审议通过了选举公司董事长、各 专门委员会委员、聘任第三届高级管理人员和证券事务代表等相关议案。现将具体 情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 8 月 6 日，公司召开职工代表大会选举董文坤先生为公司第三届董 事会职工代表董事。2025 年 8 月 22 日，公司召开 2025 年第一次临时股东大会， 审议通过了《关于董事会换届选举暨选举第三届董事会非独立董事的议案》《关 于董事会换 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688075 证券简称：安旭生物 公告编号：2025-025 杭州安旭生物科技股份有限公司 2025年第一次临时股东大会决议公告 （二） 股东大会召开的地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 81,577,525 | | 普通股股东所持有表决权数量 | 81,577,525 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.1924 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.1924 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会采用现场投票与网络投票相结合的方式对本 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-026 杭州安旭生物科技股份有限公司 第三届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第三届董事 会第一次会议于 2025 年 8 月 22 日在公司会议室以现场方式召开，会议通知于 2025 年 8 月 22 日 2025 年第一次临时股东大会审议通过后即下发通知并送达各新一届董 事，经全体董事一致同意，豁免本次会议通知时间的要求。本次会议与会董事共同 推举凌世生先生主持，会议应到董事 7 人，实到董事 7 人，高级管理人员列席了会 议。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规章、 规范性文件和《公司章程》的有关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 （一） 审议通过《关于选举公司第三届董事会董事长的议案》 同意选举凌世生先生为公司第三届董事会董事长，任期与本届董事会任期一致。 表决结果：同意 7 票 ...

法律意见书 上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会的 地址： 上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 传真: 021-20511999 电话: 021-20511000 邮编: 200120 上海市锦天城律师事务所 致:杭州安旭生物科技股份有限公司 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责,遵循了勤勉尽责和诚实信用原则,对本次股东大会所涉及的相关事 项进行了必要的核查和验证,核查了本所认为出具该法律意见书所需的相关文件、 资料,并参加了公司本次股东大会的全过程。本所保证本法律意见书所认定的事 实真实、准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、误导 性陈述或者重大遗漏,并愿意承担相应法律责任。 关于杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所(以下简称" ...

Core Viewpoint - Anxu Bio (688075) reported a decline in revenue and net profit for the first half of 2025, indicating financial challenges and increased operational costs [1] Financial Performance - Total revenue for the first half of 2025 was 230 million yuan, a decrease of 7.42% year-on-year [1] - Net profit attributable to shareholders was 59.31 million yuan, down 48.57% compared to the previous year [1] - Gross margin was 39.11%, a decrease of 4.19% year-on-year, while net margin fell to 25.76%, down 44.64% [1] - Total expenses (selling, administrative, and financial) reached 60.04 million yuan, accounting for 26.13% of total revenue, an increase of 87.61% year-on-year [1] Cash Flow and Assets - Cash and cash equivalents decreased by 64.19% to 234 million yuan, attributed to increased investments in financial products [3] - Operating cash flow per share increased significantly by 1420.52% to 0.03 yuan, due to improved collections [11] Liabilities and Debt - Short-term borrowings decreased by 100% as the company repaid its debts [4] - Other current liabilities increased by 820.77% due to dividend distribution accruals [4] Operational Insights - Revenue decline of 7.42% was influenced by customers delaying orders due to increased tariffs from the U.S. [7] - Sales expenses rose by 19.83% as the company intensified market expansion efforts [9] - Management expenses increased by 3.1% due to normal operational fluctuations [10] Business Model and Market Position - The company has nine major technology platforms in the IVD industry, focusing on various diagnostic products including drug testing and infectious disease detection [12] - The company's return on invested capital (ROIC) was 2.98%, indicating weak capital returns, while historical data shows a median ROIC of 37.7% since its listing [11]

Core Viewpoint - The company reported a resilient performance in the first half of 2025, achieving revenue of 230 million yuan and a non-net profit of 23.59 million yuan, reflecting a year-on-year growth of 24.89% [1] Group 1: Financial Performance - The company achieved revenue of 230 million yuan in the first half of 2025 [1] - The non-net profit for the same period was 23.59 million yuan, representing a year-on-year increase of 24.89% [1] Group 2: Business Strategy - The company operates in the field of POCT (Point of Care Testing) reagents and instruments, focusing on research, production, and sales [1] - The company has adopted a "dual-wheel drive" strategy, maintaining operational resilience despite increasing uncertainties in overseas markets [1] - In the domestic market, the company has obtained multiple medical device registrations, including products for respiratory virus antigen testing and chest pain triage [1] - The company is expanding its C-end market through the "Anxu Ke" brand on e-commerce platforms, establishing a dual-track development model for B-end and C-end markets [1]